Dose-escalation Study of Afatinib in Elderly Patients with EGFR mutation for Non-Small Cell Lung Cancer
Phase 1
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000016441
- Lead Sponsor
- Hirosaki University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
1)Having severe complications 2)Symptomatic brain metastases 3)Interstitial pneumonitis on chest Xray 4)Past history of severe allergic reactions to drugs 5)Pregnant or breastfeeding woman 6)Receiving steroids or immunosuppressants 7)Active infectious disease 8)Uncontrollable pleural effusion or pericardial effusion 9)Active double cancer 10)Patients whose physicians considered as inappropriate for this clinical study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To conclude maximum tolerated dose and recommended phase II dose.
- Secondary Outcome Measures
Name Time Method